Alpha synuclein emerges as leading target in Parkinson’s disease pipeline

As we approach Parkinson’s Awareness Month this April, an analysis of the global drug landscape reveals a fundamental shift in how the scientific community is tackling the condition. For decades, pharmaceutical research has been synonymous with dopamine. Today, however, the focus is moving toward the underlying biology of the condition, with a protein called alpha-synuclein emerging as the single most prominent target for future therapies. Historically, the medical world has relied on "innovator drugs" that restore or modulate dopamine signalling to manage motor symptoms like tremors and rigidity. Of the 64 approved drugs globally, 34 of them—over 50%—target dopamine receptors. This approach has been vital for improving quality of life, but it manages the effects of the condition rather than stopping its cause. A Pipeline Transformed The current research pipeline tells a different story. There are now 749 innovator drugs in development for their first approval. While dopamine-related mechanisms still represent half of the top ten targets, alpha-synuclein has surged to the top spot. There are currently 62 drugs in development specifically targeting this protein—more than double the 29 drugs targeting the D2 dopamine receptor, which is the second most popular focus. Alpha-synuclein is a protein typically found at the ends of nerve cells (presynaptic), where it helps with normal neuronal function. In the condition, this protein misfolds and aggregates into toxic clumps. These clusters are believed to be the primary culprits behind the degeneration of dopamine-producing neurons. By targeting this protein, researchers hope to move beyond symptom management and achieve "disease modification"—essentially halting the progression of the condition in its tracks. The Race for the First Approval Despite the intense focus, the field is still in its relatively early stages. Approximately 75% of the 62 alpha-synuclein products are currently in the discovery or preclinical phases. This indicates that while the biological hypothesis is strong, translating it into a viable, approved therapy is a complex and ongoing challenge. Currently, there are no approved drugs that target alpha-synuclein for any indication, but two Phase III candidates are leading the race to become the first landmark approval: Buntanetap Tartrate (Annovis Bio): An oral "small molecule" drug. According to GlobalData’s Likelihood of Approval tool, it currently has a 24% chance of success. Prasinezumab (Roche/Prothena Corp): A monoclonal antibody delivered intravenously. This candidate is rated with a 16% chance of approval. These percentages may seem modest, reflecting the significant scientific uncertainty that still surrounds the nervous system. However, even a single success among these late-stage candidates would represent a historic breakthrough. If these drugs prove effective, they could signal the beginning of an era where we don't just replace what the brain has lost, but actively protect it from further damage.